AbbVie Inc. PE Ratio 2010-2024 | ABBV

Current and historical p/e ratio for AbbVie Inc. (ABBV) from 2010 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. AbbVie Inc. PE ratio as of February 24, 2025 is 19.97.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

AbbVie Inc. PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2025-02-21 202.08 84.20
2024-12-31 177.70 $2.40 74.04
2024-09-30 195.90 $2.88 68.02
2024-06-30 168.59 $3.00 56.20
2024-03-31 177.30 $3.37 52.61
2023-12-31 149.46 $2.73 54.75
2023-09-30 142.34 $3.65 39.00
2023-06-30 127.24 $4.86 26.18
2023-03-31 149.16 $4.23 35.26
2022-12-31 149.80 $6.61 22.66
2022-09-30 123.18 $7.49 16.45
2022-06-30 139.27 $7.06 19.73
2022-03-31 146.11 $6.97 20.96
2021-12-31 120.76 $6.45 18.72
2021-09-30 95.07 $4.20 22.64
2021-06-30 98.19 $3.71 26.47
2021-03-31 93.19 $2.83 32.93
2020-12-31 91.21 $2.86 31.89
2020-09-30 73.55 $4.73 15.55
2020-06-30 81.47 $4.70 17.33
2020-03-31 62.33 $5.65 11.03
2019-12-31 71.48 $5.28 13.54
2019-09-30 60.25 $2.17 27.77
2019-06-30 57.00 $2.72 20.95
2019-03-31 62.34 $3.49 17.86
2018-12-31 70.42 $3.58 19.67
2018-09-30 71.49 $4.84 14.77
2018-06-30 69.34 $4.04 17.16
2018-03-31 70.10 $3.97 17.66
2017-12-31 71.12 $3.29 21.62
2017-09-30 64.89 $4.11 15.79
2017-06-30 52.49 $4.07 12.90
2017-03-31 46.70 $3.86 12.10
2016-12-31 44.41 $3.63 12.24
2016-09-30 44.32 $3.70 11.98
2016-06-30 43.13 $3.47 12.43
2016-03-31 39.41 $3.32 11.87
2015-12-31 40.42 $3.12 12.96
2015-09-30 36.78 $1.69 21.76
2015-06-30 45.08 $1.26 35.78
2015-03-31 38.96 $1.11 35.10
2014-12-31 43.21 $1.09 39.65
2014-09-30 37.85 $2.30 16.46
2014-06-30 36.71 $2.59 14.17
2014-03-31 33.13 $2.57 12.89
2013-12-31 33.77 $2.56 13.19
Sector Industry Market Cap Revenue
Medical Large Cap Pharma $356.743B $56.334B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly and Company (LLY) US $828.397B 67.21
Novo Nordisk A/S (NVO) DK $395.262B 26.77
Johnson & Johnson (JNJ) US $390.756B 16.25
Roche Holding AG (RHHBY) CH $264.174B 0.00
Merck & Co., Inc. (MRK) US $226.402B 11.72
Novartis AG (NVS) CH $223.511B 14.00
Pfizer Inc. (PFE) US $149.042B 8.46
Sanofi (SNY) $138.211B 13.09
Bayer Aktiengesellschaft (BAYRY) DE $22.635B 3.62
Innoviva, Inc. (INVA) US $1.132B 9.42